195 related articles for article (PubMed ID: 23300450)
41. Human DNA tumor viruses generate alternative reading frame proteins through repeat sequence recoding.
Kwun HJ; Toptan T; Ramos da Silva S; Atkins JF; Moore PS; Chang Y
Proc Natl Acad Sci U S A; 2014 Oct; 111(41):E4342-9. PubMed ID: 25271323
[TBL] [Abstract][Full Text] [Related]
42. Suppression of Epstein-Barr nuclear antigen 1 (EBNA1) by RNA interference inhibits proliferation of EBV-positive Burkitt's lymphoma cells.
Hong M; Murai Y; Kutsuna T; Takahashi H; Nomoto K; Cheng CM; Ishizawa S; Zhao QL; Ogawa R; Harmon BV; Tsuneyama K; Takano Y
J Cancer Res Clin Oncol; 2006 Jan; 132(1):1-8. PubMed ID: 16180023
[TBL] [Abstract][Full Text] [Related]
43. Identification of HLA-DP3-restricted peptides from EBNA1 recognized by CD4(+) T cells.
Voo KS; Fu T; Heslop HE; Brenner MK; Rooney CM; Wang RF
Cancer Res; 2002 Dec; 62(24):7195-9. PubMed ID: 12499257
[TBL] [Abstract][Full Text] [Related]
44. Evidence for the presentation of major histocompatibility complex class I-restricted Epstein-Barr virus nuclear antigen 1 peptides to CD8+ T lymphocytes.
Voo KS; Fu T; Wang HY; Tellam J; Heslop HE; Brenner MK; Rooney CM; Wang RF
J Exp Med; 2004 Feb; 199(4):459-70. PubMed ID: 14769850
[TBL] [Abstract][Full Text] [Related]
45. The Gly-Ala repeat modulates the interaction of Epstein-Barr virus nuclear antigen-1 with cellular chromatin.
Coppotelli G; Mughal N; Masucci MG
Biochem Biophys Res Commun; 2013 Feb; 431(4):706-11. PubMed ID: 23348225
[TBL] [Abstract][Full Text] [Related]
46. Epstein-Barr virus nuclear antigen 1 (EBNA1) induced cytotoxicity in epithelial cells is associated with EBNA1 degradation and processing.
Jones RJ; Smith LJ; Dawson CW; Haigh T; Blake NW; Young LS
Virology; 2003 Sep; 313(2):663-76. PubMed ID: 12954232
[TBL] [Abstract][Full Text] [Related]
47. The importance of exogenous antigen in priming the human CD8+ T cell response: lessons from the EBV nuclear antigen EBNA1.
Blake N; Haigh T; Shaka'a G; Croom-Carter D; Rickinson A
J Immunol; 2000 Dec; 165(12):7078-87. PubMed ID: 11120837
[TBL] [Abstract][Full Text] [Related]
48. The synthesis of truncated polypeptides for immune surveillance and viral evasion.
Cardinaud S; Starck SR; Chandra P; Shastri N
PLoS One; 2010 Jan; 5(1):e8692. PubMed ID: 20098683
[TBL] [Abstract][Full Text] [Related]
49. Structural and Functional Basis for an EBNA1 Hexameric Ring in Epstein-Barr Virus Episome Maintenance.
Deakyne JS; Malecka KA; Messick TE; Lieberman PM
J Virol; 2017 Oct; 91(19):. PubMed ID: 28701406
[TBL] [Abstract][Full Text] [Related]
50. An imperfect correlation between DNA replication activity of Epstein-Barr virus nuclear antigen 1 (EBNA1) and binding to the nuclear import receptor, Rch1/importin alpha.
Kim AL; Maher M; Hayman JB; Ozer J; Zerby D; Yates JL; Lieberman PM
Virology; 1997 Dec; 239(2):340-51. PubMed ID: 9434725
[TBL] [Abstract][Full Text] [Related]
51. Baicalein inhibits growth of Epstein-Barr virus-positive nasopharyngeal carcinoma by repressing the activity of EBNA1 Q-promoter.
Zhang Y; Wang H; Liu Y; Wang C; Wang J; Long C; Guo W; Sun X
Biomed Pharmacother; 2018 Jun; 102():1003-1014. PubMed ID: 29710517
[TBL] [Abstract][Full Text] [Related]
52. Expression of VCA (viral capsid antigen) and EBNA1 (Epstein-Barr-virus-encoded nuclear antigen 1) genes of Epstein-Barr virus in Pichia pastoris and application of the products in a screening test for patients with nasopharyngeal carcinoma.
Hu B; Hong G; Li Z; Xu J; Zhu Z; Li L
Biotechnol Appl Biochem; 2007 May; 47(Pt 1):59-69. PubMed ID: 17129209
[TBL] [Abstract][Full Text] [Related]
53. B Cell-Specific Transcription Activator PAX5 Recruits p300 To Support EBNA1-Driven Transcription.
Liu CD; Lee HL; Peng CW
J Virol; 2020 Mar; 94(7):. PubMed ID: 31941781
[TBL] [Abstract][Full Text] [Related]
54. Optimal transactivation by Epstein-Barr nuclear antigen 1 requires the UR1 and ATH1 domains.
Singh G; Aras S; Zea AH; Koochekpour S; Aiyar A
J Virol; 2009 May; 83(9):4227-35. PubMed ID: 19244333
[TBL] [Abstract][Full Text] [Related]
55. Repeat sequence of Epstein-Barr virus-encoded nuclear antigen 1 protein interrupts proteasome substrate processing.
Zhang M; Coffino P
J Biol Chem; 2004 Mar; 279(10):8635-41. PubMed ID: 14688254
[TBL] [Abstract][Full Text] [Related]
56. EBP2, a human protein that interacts with sequences of the Epstein-Barr virus nuclear antigen 1 important for plasmid maintenance.
Shire K; Ceccarelli DF; Avolio-Hunter TM; Frappier L
J Virol; 1999 Apr; 73(4):2587-95. PubMed ID: 10074103
[TBL] [Abstract][Full Text] [Related]
57. Dual stimulation of Epstein-Barr Virus (EBV)-specific CD4+- and CD8+-T-cell responses by a chimeric antigen construct: potential therapeutic vaccine for EBV-positive nasopharyngeal carcinoma.
Taylor GS; Haigh TA; Gudgeon NH; Phelps RJ; Lee SP; Steven NM; Rickinson AB
J Virol; 2004 Jan; 78(2):768-78. PubMed ID: 14694109
[TBL] [Abstract][Full Text] [Related]
58. EBNA1: Oncogenic Activity, Immune Evasion and Biochemical Functions Provide Targets for Novel Therapeutic Strategies against Epstein-Barr Virus- Associated Cancers.
Wilson JB; Manet E; Gruffat H; Busson P; Blondel M; Fahraeus R
Cancers (Basel); 2018 Apr; 10(4):. PubMed ID: 29642420
[TBL] [Abstract][Full Text] [Related]
59. The V-val subtype Epstein-Barr virus nuclear antigen 1 promotes cell survival after serum withdrawal.
Chao M; Wang HN; Lu YJ; Chang YS; Yu JS
Oncol Rep; 2015 Feb; 33(2):958-66. PubMed ID: 25434292
[TBL] [Abstract][Full Text] [Related]
60. Increased frequency and broadened specificity of latent EBV nuclear antigen-1-specific T cells in multiple sclerosis.
Lünemann JD; Edwards N; Muraro PA; Hayashi S; Cohen JI; Münz C; Martin R
Brain; 2006 Jun; 129(Pt 6):1493-506. PubMed ID: 16569670
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
